* * * * * * * * * * Welcome to STN International * * * * * * * * * *
` NEWS 1 JUN 26 COMPENDEX - New Fields for Author Identifier and URL
` NEWS 2 JUN 30 Numeric Property Search Added to USPATFULL and USPAT2
` NEWS 3 AUG 5 Chemical and Technology Databases RAPRA, CEABA,
`and TEMA Add Numeric Property Search
` NEWS 4 OCT 7 EP Appeal Data from European Patent Register Added to
`INPADOCDB and INPAFAMDB
` NEWS 5 NOV 15 Enhanced INPADOCDB and INPAFAMDB Files
` NEWS 6 NOV 23 Claims Access in CA/CAplus: WIPO, United States, and China
`for 1999 - Present.
` NEWS 7 DEC 1 Engineering Flagship Database Inspec Reaches
`Milestone 20 Million Total Records
` NEWS 8 DEC 1 Full-Text Patent Documents from German Democratic
`Republic Added to DEFULL
` NEWS 9 FEB 7 Patent Status Indicators in CA/CAplus
` NEWS 10 FEB 16 ReaxysFileSub and companion bibliographic
`database ReaxysFileBib new on STNext(R)
` NEWS 11 APR 12 New Version of the EPFULL (European Patent Full Text
`Database) Launched on STN
` NEWS 12 APR 12 Analytical Abstracts Enhancements Increase Value to Users
` NEWS 13 APR 13 INSPEC Reload Features Numeric Property Searching, Cited
`References and DOIs
` NEWS 14 MAY 10 May 2021 Update to Emtree(R) Now Available on STN
` NEWS 15 SEP 6 New Russian Patent Full Text Database RUFULL Launched on STN
` NEWS 16 SEP 6 NTIS Reload on STNext Resumes Updating; Introduces Numeric
`Property Searching and SLART Improvements
` NEWS 17 SEP 11 September 2021 Update to Emtree(R) Now Available on STN
` NEWS 18 OCT 4 MARPAT(R) Enhanced with Patent Status Data
` NEWS HOURS STN Operating Hours Plus Help Desk Availability
` NEWS LOGIN Welcome Banner and News Items
` NEWS TRAINING Find instructor-led and self-directed training opportunities
`Enter NEWS followed by the item number or name to see news on that
`specific topic.
`For pricing information enter HELP PRICE or HELP COST at any arrow prompt.
` All use of STN is subject to the provisions of the STN customer
` agreement. This agreement limits use to scientific research. Use
` for software development or design, implementation of commercial
` gateways, or use of CAS and STN data in the building of commercial
` products is prohibited and may result in loss of user privileges
` and other penalties.
`Access the latest version of STN.
`Log into STNext with your STN login ID at https://www.stn.org
`STNext is updated frequently. To see the latest STNext Release Notes, click
`https://www.stn.org/help/stnext/ReleaseNotes.htm
`* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *
`
`IPR2021-00406
`United Therapeutics EX2045
`Page 1 of 11
`
`

`

`FILE 'HOME' ENTERED AT 11:01:37 ON 04 NOV 2021
`ENTER COST CENTER (NONE):fil caplus
`
`CHARGED TO COST=FIL CAPLUS
`
`=> fil caplus
`
`COST IN U.S. DOLLARS SINCE FILE TOTAL
` ENTRY SESSION
`FULL ESTIMATED COST 0.21 0.21
`
`FILE 'CAPLUS' ENTERED AT 11:02:30 ON 04 NOV 2021
`USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
`COPYRIGHT (C) 2021 AMERICAN CHEMICAL SOCIETY (ACS)
`CHARGED TO COST=FIL CAPLUS
`
`
`Copyright of the articles to which records in this database refer is
`held by the publishers listed in the PUBLISHER (PB) field (available
`for records published or updated in Chemical Abstracts after December
`26, 1996), unless otherwise indicated in the original publications.
`
`The CA Lexicon is the copyrighted intellectual property of the
`American Chemical Society and is provided to assist you in searching
`databases on STN. Any dissemination, distribution, copying, or storing
`of this information, without the prior written consent of CAS, is
`strictly prohibited.
`
`FILE COVERS 1907 - 4 Nov 2021 VOL 176 ISS 8
`FILE LAST UPDATED: 3 Nov 2021 (20211103/ED)
`
`CAS Information Use Policies apply and are available at:
`
`http://www.cas.org/legal/infopolicy
`
`This file contains CAS Registry Numbers for easy and accurate
`substance identification.
`
`=> s voswickel r?/au
`
`L1 0 VOSWICKEL R?/AU
`
`=> s voswinckel r?/au
`
`L2 73 VOSWINCKEL R?/AU
`
`=> s l2 and treprostinil/ti
`
` 267 TREPROSTINIL/TI
`L3 8 L2 AND TREPROSTINIL/TI
`
`=> d scan l3
`
`
`L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN
`CC 1-8 (Pharmacology)
`TI Addition of inhaled treprostinil to oral therapy for pulmonary arterial
`
`Page 2 of 11
`
`

`

` hypertension
`ST pulmonary arterial hypertension treprostinil sodium antihypertensive
` sildenafil bosentan exercise
`IT Antihypertensives
` Exercise
` Human
` Inhalation drug delivery systems
` Oral drug delivery systems
` Pulmonary hypertension
` (addn. of inhaled treprostinil sodium to oral therapy with either
` bosentan or sildenafil was safe, well tolerated, improved exercise
` capacity and quality of life in patient with pulmonary arterial
` hypertension)
`IT 686719-75-5, N-Terminal pro-brain natriuretic peptide
` RL: BSU (Biological study, unclassified); BIOL (Biological study)
` (addn. of inhaled treprostinil sodium to oral therapy with either
` bosentan or sildenafil improved N-terminal pro-brain natriuretic
` peptide level in patient with pulmonary arterial hypertension)
`IT 139755-83-2, Sildenafil 147536-97-8, Bosentan 289480-64-4,
` Treprostinil sodium
` RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
` (Biological study); USES (Uses)
` (addn. of inhaled treprostinil sodium to oral therapy with either
` bosentan or sildenafil was safe, well tolerated, improved exercise
` capacity and quality of life in patient with pulmonary arterial
` hypertension)
`
`HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):8
`
`
`L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN
`IPCI A61K0031-557 [I]; A61K0009-72 [I]; A61K0009-12 [I]; A61K0031-557 [I];
` A61K0031-557 [I]; A61K0009-12 [I]; A61K0009-12 [I]; A61K0009-72 [I];
` A61K0009-72 [I]
`IPCR A61K0031-557 [I]; A61K0009-12 [I]; A61K0009-72 [I]
`CPCI A61K0009-008 [I]; A61K0031-192 [I]; A61K0031-557 [I]; A61P0009-00 [I];
` A61P0009-12 [I]; A61P0011-00 [I]; A61P0043-00 [I]; A61K0009-00 [I];
` A61K0009-12 [I]; A61K0009-0078 [I]
`ECLA A61K0031-557; A61K0009-00M20B6; A61K0031-557; A61K0009-00M20B6
`CC 63-6 (Pharmaceuticals)
` Section cross-reference(s): 1, 4
`TI Inhalant containing treprostinil and its derivatives in a metered dose
` inhaler
`ST inhalant treprostinil deriv metered dose inhaler
`IT Toxicity
` (acute; inhalant contg. treprostinil and derivs. in metered dose
` inhaler)
`IT Circulation
` Dizziness
` Headache
` Human
` Inhalation drug delivery systems
` Medical inhalers
` Nausea
` (inhalant contg. treprostinil and derivs. in metered dose inhaler)
`IT 81846-19-7, Treprostinil 289480-64-4, Treprostinil sodium
` RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
`
`Page 3 of 11
`
`

`

` activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological
` study); USES (Uses)
` (inhalant contg. treprostinil and derivs. in metered dose inhaler)
`IT 21829-25-4, Nifedipine 35121-78-9, Prostacyclin 42399-41-7, Diltiazem
` 78919-13-8, Iloprost 81846-19-7D, Treprostinil, derivs. 88150-42-9,
` Amlodipine 88430-50-6, Beraprost 139755-83-2, Sildenafil
` 147536-97-8, Bosentan 171596-29-5, Tadalafil 177036-94-1, Ambrisentan
` 184036-34-8, Sitaxsentan 224785-90-4, Vardenafil
` RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
` (inhalant contg. treprostinil and derivs. in metered dose inhaler)
`
`L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN
`CC 1-0 (Pharmacology)
`TI Inhaled treprostinil: a therapeutic review
`ST review antihypertensive inhaled treprostinil pulmonary arterial
` hypertension
`IT Antihypertensives
` Bioavailability
` Cardiovascular system
` Human
` Inhalation drug delivery systems
` Pulmonary hypertension
` (therapeutic review of inhaled treprostinil)
`IT 81846-19-7, Treprostinil
` RL: BSU (Biological study, unclassified); BIOL (Biological study)
` (therapeutic review of inhaled treprostinil)
`
`L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN
`CC 1-9 (Pharmacology)
` Section cross-reference(s): 63
`TI Metered dose inhaler delivery of treprostinil for the treatment of
` pulmonary hypertension
`ST metered dose inhaler treprostinil antihypertensive pulmonary vasodilator
` lung hypertension
`IT Medical inhalers
` (Respimat; metered dose inhaler delivery of treprostinil for treatment
` of pulmonary hypertension)
`IT Human
` Inhalation drug delivery systems
` Pulmonary antihypertensives
` Pulmonary hypertension
` Vascular resistance
` (metered dose inhaler delivery of treprostinil for treatment of
` pulmonary hypertension)
`IT Vasodilators
` (pulmonary; metered dose inhaler delivery of treprostinil for treatment
` of pulmonary hypertension)
`IT 289480-64-4, Treprostinil sodium
` RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
` (Biological study); USES (Uses)
` (Respimat; metered dose inhaler delivery of treprostinil for treatment
` of pulmonary hypertension)
`
`L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN
`CC 1-8 (Pharmacology)
`TI Favorable effects of inhaled treprostinil in severe pulmonary
` hypertension. Results from randomized controlled pilot studies
`
`Page 4 of 11
`
`

`

`ST treprostinil iloprost pulmonary hypertension pharmacokinetics vasodilator
` antihypertensive
`IT Blood pressure
` (inhaled treprostinil and iloprost were comparable in their ability to
` decrease pulmonary arterial pressure in severe pulmonary hypertension
` patient)
`IT Vascular resistance
` (inhaled treprostinil and iloprost were comparable in their ability to
` decrease pulmonary vascular resistance in severe pulmonary hypertension
` patient)
`IT Antihypertensives
` Human
` Pulmonary hypertension
` Vasodilators
` (inhaled treprostinil exerted sustained pulmonary vasodilation compared
` to iloprost and was well tolerated at low dose with reduced inhalation
` time in severe pulmonary hypertension patient)
`IT Pharmacokinetics
` (inhaled treprostinil revealed acceptable pharmacokinetics
` characteristic in severe pulmonary hypertension patient)
`IT Cardiac contraction
` (systemic arterial pressure was unaffected by treprostinil while it was
` decreased by iloprost in severe pulmonary hypertension patient)
`IT 81846-19-7, Treprostinil
` RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
` activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological
` study); USES (Uses)
` (inhaled treprostinil exerted sustained pulmonary vasodilation compared
` to iloprost and was well tolerated at low dose with reduced inhalation
` time in severe pulmonary hypertension patient)
`IT 78919-13-8, Iloprost
` RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
` activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
` (inhaled treprostinil exerted sustained pulmonary vasodilation compared
` to iloprost and was well tolerated at low dose with reduced inhalation
` time in severe pulmonary hypertension patient)
`IT 7782-44-7, Oxygen, biological studies
` RL: BSU (Biological study, unclassified); BIOL (Biological study)
` (neither treprostinil nor iloprost affected pulmonary gas exchange in
` severe pulmonary hypertension patient)
`
`L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN
`CC 1-12 (Pharmacology)
`TI Treprostinil inhibits the adhesion and differentiation of fibrocytes via
` the cyclic adenosine monophosphate-dependent and Ras-proximate
` protein-dependent inactivation of extracellular regulated kinase
`ST treprostinil antihypertensive cAMP Ras ERK fibrocyte adhesion
` differentiation
`IT Antihypertensives
` Cell adhesion
` Cell differentiation
` Fibroblast
` Hypoxia
` Mononuclear leukocyte
` Phosphorylation
` Pulmonary hypertension
` Signal transduction
`
`Page 5 of 11
`
`

`

` (treprostinil inhibits adhesion and differentiation of fibrocytes via
` cyclic adenosine monophosphate dependent and Ras-proximate
` protein-dependent inactivation of extracellular regulated kinase)
`IT Integrin β1
` Integrin β2
` Prostacyclin receptors
` Transcription factor CREB
` RL: BSU (Biological study, unclassified); BIOL (Biological study)
` (treprostinil inhibits adhesion and differentiation of fibrocytes via
` cyclic adenosine monophosphate dependent and Ras-proximate
` protein-dependent inactivation of extracellular regulated kinase)
`IT 60-92-4, CAMP 137632-07-6, ERK1 137632-08-7 142008-29-5, Protein
` kinase A
` RL: BSU (Biological study, unclassified); BIOL (Biological study)
` (treprostinil inhibits adhesion and differentiation of fibrocytes via
` cyclic adenosine monophosphate dependent and Ras-proximate
` protein-dependent inactivation of extracellular regulated kinase)
`IT 81846-19-7, Treprostinil
` RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
` (Biological study); USES (Uses)
` (treprostinil inhibits adhesion and differentiation of fibrocytes via
` cyclic adenosine monophosphate dependent and Ras-proximate
` protein-dependent inactivation of extracellular regulated kinase)
`
`L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN
`CC 1-8 (Pharmacology)
`TI Acute effects of the combination of sildenafil and inhaled treprostinil
` on hemodynamics and gas exchange in pulmonary hypertension
`ST sildenafil treprostinil inhalant vasodilator pulmonary hypertension
`IT Cardiovascular system
` Circulation
` Combination chemotherapy
` Human
` Inhalation drug delivery systems
` Pulmonary hypertension
` Vasodilators
` (acute effects of sildenafil and inhaled treprostinil combination on
` hemodynamics and gas exchange in pulmonary hypertension)
`IT Drug interactions
` (additive; acute effects of sildenafil and inhaled treprostinil
` combination on hemodynamics and gas exchange in pulmonary hypertension)
`IT 81846-19-7, Treprostinil 139755-83-2, Sildenafil
` RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological
` activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
` (acute effects of sildenafil and inhaled treprostinil combination on
` hemodynamics and gas exchange in pulmonary hypertension)
`
`L3 8 ANSWERS CAPLUS COPYRIGHT 2021 ACS on STN
`CC 1-8 (Pharmacology)
`TI Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to
` Bosentan in Pulmonary Arterial Hypertension
`ST pulmonary arterial hypertension treprostinil bosentan pharmacokinetics
`IT Blood pressure
` (inhaled treprostinil as add-on therapy to bosentan decreased pulmonary
` arterial pressure in patient with pulmonary arterial hypertension)
`IT Vascular resistance
` (inhaled treprostinil as add-on therapy to bosentan decreased pulmonary
`
`Page 6 of 11
`
`

`

` vascular resistance in patient with pulmonary arterial hypertension)
`IT Exercise
` (inhaled treprostinil as add-on therapy to bosentan improved exercise
` capacity in patient with pulmonary arterial hypertension)
`IT Antihypertensives
` Human
` Pulmonary hypertension
` (inhaled treprostinil as add-on therapy to bosentan was safe, well
` tolerated and improved exercise capacity, functional class and
` pulmonary hemodynamics in patient with pulmonary arterial hypertension)
`IT Pharmacokinetics
` (treprostinil reached systemic circulation in dose-dependent fashion in
` pulmonary arterial hypertension patient already on bosentan)
`IT 81846-19-7, Treprostinil
` RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU
` (Therapeutic use); BIOL (Biological study); USES (Uses)
` (inhaled treprostinil as add-on therapy to bosentan was safe, well
` tolerated and improved exercise capacity, functional class and
` pulmonary hemodynamics in patient with pulmonary arterial hypertension)
`IT 147536-97-8, Bosentan
` RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
` (Biological study); USES (Uses)
` (inhaled treprostinil as add-on therapy to bosentan was safe, well
` tolerated and improved exercise capacity, functional class and
` pulmonary hemodynamics in patient with pulmonary arterial hypertension)
`
`ALL ANSWERS HAVE BEEN SCANNED
`
`
`=> d l3 1-8
`
`
`L3 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2021 ACS on STN
`
`AN 2012:249377 CAPLUS Full-text
`DN 157:651671
`TI Inhaled treprostinil: a therapeutic review
`AU Channick, Richard N.; Voswinckel, Robert; Rubin, Lewis J.
`CS Pulmonary Hypertension Program, Massachusetts General Hospital, Boston,
` MA, USA
`SO Drug Design, Development and Therapy (2012), 6, 19-28
` CODEN: DDDTAQ; ISSN: 1177-8881
`DOI 10.2147/DDDT.S19281
`PB Dove Medical Press Ltd.
`DT Journal; General Review; (online computer file)
`LA English
`OSC.G 18 THERE ARE 18 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
`RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
` ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2021 ACS on STN
`
`AN 2011:1338228 CAPLUS Full-text
`DN 156:525395
`TI Treprostinil inhibits the adhesion and differentiation of fibrocytes via
` the cyclic adenosine monophosphate-dependent and Ras-proximate
` protein-dependent inactivation of extracellular regulated kinase
`
`Page 7 of 11
`
`

`

`AU Nikam, Vandana S.; Wecker, Gesa; Schermuly, Ralph; Rapp, Ulf; Szelepusa,
` Kirsten; Seeger, Werner; Voswinckel, Robert
`CS Department of Lung Development and Remodeling, Max Planck Institute for
` Heart and Lung Research, Bad Nauheim, Germany
`SO American Journal of Respiratory Cell and Molecular Biology (2011), 45(4),
` 692-703
` CODEN: AJRBEL; ISSN: 1044-1549
` URL: http://ajrcmb.atsjournals.org/cgi/reprint/45/4/692
`DOI 10.1165/rcmb.2010-0240OC
`PB American Thoracic Society
`DT Journal; (online computer file)
`LA English
`OSC.G 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)
`RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
` ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2021 ACS on STN
`
`AN 2010:765129 CAPLUS Full-text
`DN 154:25370
`TI Addition of inhaled treprostinil to oral therapy for pulmonary arterial
` hypertension
`AU McLaughlin, Vallerie V.; Benza, Raymond L.; Rubin, Lewis J.; Channick,
` Richard N.; Voswinckel, Robert; Tapson, Victor F.; Robbins, Ivan M.;
` Olschewski, Horst; Rubenfire, Melvyn; Seeger, Werner
`CS University of Michigan Health System, Ann Arbor, MI, USA
`SO Journal of the American College of Cardiology (2010), 55(18), 1915-1922
` CODEN: JACCDI; ISSN: 0735-1097
`DOI 10.1016/j.jacc.2010.01.027
`PB Elsevier Inc.
`DT Journal
`LA English
`OSC.G 150 THERE ARE 150 CAPLUS RECORDS THAT CITE THIS RECORD (151 CITINGS)
`RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
` ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2021 ACS on STN
`
`AN 2009:104886 CAPLUS Full-text
`DN 150:344978
`TI Metered dose inhaler delivery of treprostinil for the treatment of
` pulmonary hypertension
`AU Voswinckel, Robert; Reichenberger, Frank; Gall, Henning; Schmehl,
` Thomas; Gessler, Tobias; Schermuly, Ralph Theo; Grimminger, Friedrich;
` Rubin, Lewis J.; Seeger, Werner; Ghofrani, Hossein A.; Olschewski, Horst
`CS University of Giessen Lung Center, Department of Internal Medicine,
` University Hospital Giessen, Giessen, 35392, Germany
`SO Pulmonary Pharmacology & Therapeutics (2009), 22(1), 50-56
` CODEN: PPTHFJ; ISSN: 1094-5539
`DOI 10.1016/j.pupt.2008.11.009
`PB Elsevier Ltd.
`DT Journal
`LA English
`OSC.G 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)
`RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
` ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`
`Page 8 of 11
`
`

`

`L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2021 ACS on STN
`
`AN 2008:1090706 CAPLUS Full-text
`DN 149:394272
`TI Acute effects of the combination of sildenafil and inhaled treprostinil
` on hemodynamics and gas exchange in pulmonary hypertension
`AU Voswinckel, Robert; Reichenberger, Frank; Enke, Beate; Kreckel, Andre;
` Krick, Stefanie; Gall, Henning; Schermuly, Ralph Theo; Grimminger,
` Friedrich; Rubin, Lewis J.; Olschewski, Horst; Seeger, Werner; Ghofrani,
` Hossein A.
`CS Department of Internal Medicine, University of Giessen Lung Center,
` University Hospital Giessen and Marburg GmbH, Giessen, Germany
`SO Pulmonary Pharmacology & Therapeutics (2008), 21(5), 824-832
` CODEN: PPTHFJ; ISSN: 1094-5539
`DOI 10.1016/j.pupt.2008.07.003
`PB Elsevier Ltd.
`DT Journal
`LA English
`OSC.G 30 THERE ARE 30 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)
`RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
` ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2021 ACS on STN
`PatentPak PDF | PatentPak PDF+ | PatentPak Interactive
`AN 2007:1330873 CAPLUS Full-text
`DN 147:528206
`TI Inhalant containing treprostinil and its derivatives in a metered dose
` inhaler
`IN Olschewski, Horst; Roscigno, Robert; Rubin, Lewis J.; Schmehl, Thomas;
` Seeger, Werner; Sterritt, Carl; Voswinckel, Robert
`PA United Therapeutics Corporation, USA
`SO PCT Int. Appl., 49 pp.
` CODEN: PIXXD2
`DT Patent
`LA English
`FAN.CNT 1
`PPPI
` PATENT NO. KIND DATE LANGUAGE PatentPak
` --------------- ---- -------- ---------- ------------------------
` WO 2007134292 A2 20071122 English PDF | PDF+ | Interactive
` CA 2654492 C 20170627 English PDF
` KR 1390579 B1 20140519 Korean PDF
` EP 2026816 B1 20181024 English PDF
` CN 101495122 B 20111005 Chinese PDF
` JP 5797376 B2 20151021 Japanese PDF
` US 9358240 B2 20160607 English PDF
` US 20120216801 A1 20120830 English PDF
` US 9339507 B2 20160517 English PDF
` JP 2014114269 A 20140626 Japanese PDF
` JP 2016006066 A 20160114 Japanese PDF
` US 20160143868 A1 20160526 English PDF
` US 10376525 B2 20190813 English PDF
` JP 2019112434 A 20190711 Japanese PDF
` US 20190365778 A1 20191205 English PDF
` US 20200171044 A1 20200604 English PDF
` US 10716793 B2 20200721 English PDF
`PI
`
`Page 9 of 11
`
`

`

` PATENT NO. KIND DATE APPLICATION NO. DATE
` --------------- ---- -------- --------------------- --------
` WO 2007134292 A2 20071122 WO 2007-US68884 20070514
` WO 2007134292 A3 20080110
` CA 2654492 A1 20071122 CA 2007-2654492 20070514
` CA 2654492 C 20170627
` US 20080200449 A1 20080821 US 2007-748205 20070514
` KR 2009007797 A 20090120 KR 2008-7030212 20070514
` KR 1390579 B1 20140519
` EP 2026816 A2 20090225 EP 2007-783735 20070514
` EP 2026816 B1 20181024
` CN 101495122 A 20090729 CN 2007-80023937 20070514
` CN 101495122 B 20111005
` JP 2009537246 T 20091029 JP 2009-511194 20070514
` JP 5797376 B2 20151021
` ES 2707548 T3 20190404 ES 2007-783735 20070514
` IN 2008DN10147 A 20090515 IN 2008-DN10147 20081205
` US 20100076083 A1 20100325 US 2009-591200 20091112
` US 9358240 B2 20160607
` US 20120216801 A1 20120830 US 2012-13469854 20120511
` US 9339507 B2 20160517
` JP 2014114269 A 20140626 JP 2013-185229 20130906
` JP 2016006066 A 20160114 JP 2015-142794 20150717
` US 20160143868 A1 20160526 US 2016-15011999 20160201
` US 10376525 B2 20190813
` JP 2019112434 A 20190711 JP 2019-38370 20190304
` US 20190365778 A1 20191205 US 2019-16536954 20190809
` US 20200171044 A1 20200604 US 2020-16778662 20200131
` US 10716793 B2 20200721
`PRAI US 2006-60800016 P 20060515
` JP 2009-511194 A3 20070514
` US 2007-748205 A1 20070514
` WO 2007-US68884 W 20070514
` US 2009-591200 A3 20091112
` US 2012-13469854 A3 20120511
` JP 2015-142794 A3 20150717
` US 2016-15011999 A1 20160201
` US 2019-16536954 A1 20190809
`PSPI
` PATENT NO. KIND STATUS STATUS DATE
` --------------- ---- ------------- -----------
` WO 2007134292 A2 Dead 20201201
` WO 2007134292 A3 Dead 20201202
` CA 2654492 A1 Alive 20201121
` CA 2654492 C Alive 20201120
` US 20080200449 A1 Dead 20201121
` KR 2009007797 A Alive 20201121
` KR 1390579 B1 Alive 20201120
` EP 2026816 A2 Indeterminate 20201107
` EP 2026816 B1 Indeterminate 20201107
` CN 101495122 A Alive 20201121
` CN 101495122 B Alive 20201121
` JP 5797376 B2 Alive 20201121
` ES 2707548 T3 Alive 20201121
` US 20100076083 A1 Alive 20201120
` US 9358240 B2 Alive 20201121
` US 20120216801 A1 Alive 20201121
`
`Page 10 of 11
`
`

`

` US 9339507 B2 Alive 20201121
` JP 2014114269 A Dead 20201120
` JP 2016006066 A Dead 20201120
` US 20160143868 A1 Alive 20201120
` US 10376525 B2 Alive 20201120
` JP 2019112434 A Alive 20201121
` US 20190365778 A1 Alive 20201120
` US 20200171044 A1 Alive 20201121
` US 10716793 B2 Alive 20201121
`ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
`OS CASFORMULTNS 2007:1330873
`OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
`
`L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2021 ACS on STN
`
`AN 2006:1081563 CAPLUS Full-text
`DN 147:23150
`TI Favorable effects of inhaled treprostinil in severe pulmonary
` hypertension. Results from randomized controlled pilot studies
`AU Voswinckel, Robert; Enke, Beate; Reichenberger, Frank; Kohstall, Markus;
` Kreckel, Andree; Krick, Stefanie; Gall, Henning; Gessler, Tobias; Schmehl,
` Thomas; Ghofrani, Hossein A.; Schermuly, Ralph Theo; Grimminger,
` Friedrich; Rubin, Lewis J.; Seeger, Werner; Olschewski, Horst
`CS Department of Internal Medicine, University Hospital Giessen, Giessen,
` Germany
`SO Journal of the American College of Cardiology (2006), 48(8), 1672-1681
` CODEN: JACCDI; ISSN: 0735-1097
`DOI 10.1016/j.jacc.2006.06.062
`PB Elsevier Inc.
`DT Journal
`LA English
`OSC.G 64 THERE ARE 64 CAPLUS RECORDS THAT CITE THIS RECORD (65 CITINGS)
`RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
` ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2021 ACS on STN
`
`AN 2006:1023703 CAPLUS Full-text
`DN 146:55118
`TI Safety and Efficacy of Inhaled Treprostinil as Add-On Therapy to
` Bosentan in Pulmonary Arterial Hypertension
`AU Channick, Richard N.; Olschewski, Horst; Seeger, Werner; Staub, Ted;
` Voswinckel, Robert; Rubin, Lewis J.
`CS UCSD Medical Center, La Jolla, CA, USA
`SO Journal of the American College of Cardiology (2006), 48(7), 1433-1437
` CODEN: JACCDI; ISSN: 0735-1097
`DOI 10.1016/j.jacc.2006.05.070
`PB Elsevier Inc.
`DT Journal
`LA English
`OSC.G 47 THERE ARE 47 CAPLUS RECORDS THAT CITE THIS RECORD (47 CITINGS)
`RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
` ALL CITATIONS AVAILABLE IN THE RE FORMAT
`
`
`=>
`
`Page 11 of 11
`
`